Adicet Bio to Participate in Upcoming Investor Conferences

MENLO PARK, Calif. and BOSTON, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that company management will participate in two upcoming virtual investor conferences in September.

Details of the events are as follows:

H.C. Wainwright 23rd Annual Global Investment Conference, September 13-15, 2021 Registered attendees can access the recorded presentation on-demand starting September 13, 2021 at 7:00 AM ET for the duration of the conference.

2021 Cantor Virtual Global Healthcare Conference, September 27-30, 2021Chen Schor, President and Chief Executive Officer, will participate in a fireside chat on Monday, September 27, 2021 at 10:00 AM ET.

Live audio webcasts of the of the presentation and fireside chat can be accessed on the Investors section of Adicet Bio’s website at https://investor.adicetbio.com. Archived replays will be available for 30 days following the presentations.

About Adicet Bio, Inc.Adicet Bio, Inc. is a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. For more information, please visit our website at http://www.adicetbio.com.

Adicet Bio., Inc.Investor and Media Contacts

Anne Bowdidge[email protected]

Janhavi MohiteStern Investor Relations, Inc.212-362-1200[email protected]

You May Also Be Interested In

• JUST PUBLISHED! Glenn S. Wrightson's Debut Novel, Through Ed Dempsey's Eyes: A Matter of Thorny Justice, Features How The Legal System Weighs Intent and Obsessive Love Against Social Norms
• The Nose Knows: Why NeOnc’s Patent Portfolio Could Make NTHI More Than a One-Drug Biotech
• News Release for Early Warning Report Regarding Canadian Copper Inc.